HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Breast cancer risk associated with genotype polymorphism of the catechol estrogen-metabolizing genes: a multigenic study on cancer susceptibility.

Abstract
Estrogen has been suggested to trigger breast cancer development via an initiating mechanism involving its metabolite, catechol estrogen (CE). To examine this hypothesis, we carried out a multigenic case-control study of 469 incident breast cancer patients and 740 healthy controls to define the role of important genes involved in the different metabolic steps that protect against the potentially harmful effects of CE metabolism. We studied the 3 genes involved in CE detoxification by conjugation reactions involving methylation (catechol-O-methyltransferase, COMT), sulfation (sulfotransferase 1A1, SULT1A1), or glucuronidation (UDP-glucuronosyltransferase 1A1, UGT1A1), one (manganese superoxide dismutase, MnSOD) involved in protection against reactive oxidative species-mediated oxidation during the conversion of CE-semiquinone (CE-SQ) to CE-quinone (CE-Q), and 2 of the glutathione S-transferase superfamily, GSTM1 and GSTT1, involved in CE-Q metabolism. Support for this hypothesis came from the observations that (i) there was a trend toward an increased risk of breast cancer in women harboring a greater number of putative high-risk genotypes of these genes (p < 0.05); (ii) this association was stronger and more significant in those women who were more susceptible to estrogen [no history of pregnancy or older (> or =26 years) at first full-term pregnancy (FFTP)]; and (iii) the risks associated with having one or more high-risk genotypes were not the same in women having experienced different menarche-to-FFTP intervals, being more significant in women having been exposed to estrogen for a longer period (> or =12 years) before FFTP. Furthermore, because CE-Q can attack DNA, leading to the formation of double-strand breaks (DSB), we examined whether the relationship between cancer risk and the genotypic polymorphism of CE-metabolizing genes was modified by the genotypes of DSB repair genes, and found that a joint effect of CE-metabolizing genes and one of the two DSB repair pathways, the homologous recombination pathway, was significantly associated with breast cancer development. Based on comprehensive CE metabolizing gene profiles, our study provides support to the hypotheses that breast cancer can be initiated by estrogen exposure and that increased estrogen exposure confers a higher risk of breast cancer by causing DSB to DNA.
AuthorsTing-Chih Cheng, Shou-Tung Chen, Chiun-Sheng Huang, Yi-Ping Fu, Jyh-Cherng Yu, Chun-Wen Cheng, Pei-Ei Wu, Chen-Yang Shen
JournalInternational journal of cancer (Int J Cancer) Vol. 113 Issue 3 Pg. 345-53 (Jan 20 2005) ISSN: 0020-7136 [Print] United States
PMID15455371 (Publication Type: Comparative Study, Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Biomarkers, Tumor
  • Estrogens, Catechol
  • DNA
  • Superoxide Dismutase
  • Catechol O-Methyltransferase
  • UGT1A1 enzyme
  • Glucuronosyltransferase
  • glutathione S-transferase T1
  • Glutathione Transferase
  • glutathione S-transferase M1
  • Arylsulfotransferase
  • SULT1A1 protein, human
Topics
  • Adult
  • Aged
  • Aged, 80 and over
  • Arylsulfotransferase (genetics)
  • Biomarkers, Tumor (genetics)
  • Breast Neoplasms (enzymology, epidemiology, genetics)
  • Carcinoma, Ductal, Breast (enzymology, epidemiology, genetics)
  • Case-Control Studies
  • Catechol O-Methyltransferase (genetics)
  • DNA (genetics)
  • DNA Repair
  • Estrogens, Catechol (genetics, metabolism)
  • Female
  • Genetic Predisposition to Disease
  • Genotype
  • Glucuronosyltransferase (genetics)
  • Glutathione Transferase (genetics)
  • Humans
  • Middle Aged
  • Polymorphism, Genetic
  • Risk Factors
  • Superoxide Dismutase (genetics)
  • Taiwan (epidemiology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: